THE ROUNDS REPORT
The antibiotic you've been second-guessing for MSSA bacteremia just got a definitive answer. The screening test you've been recommending for decades finally has randomized data. And the results are more complicated than the guidelines suggest. Also, a new anticoagulant mechanism just produced the most promising secondary stroke prevention trial in years.
There's plenty more. A triple hormone receptor agonist delivers results that make every prior GLP-1 look like a warm-up act. And MASLD — the silent epidemic filling your outpatient panels — gets its strongest pharmacologic signal yet.
Let's get into it.
THE BIG FIVE GAME-CHANGERS
1. SNAP: Cefazolin Is Now the Evidence-Based Default for MSSA Bacteremia
Infectious Disease / Hospital Medicine
The cefazolin-versus-antistaphylococcal-penicillin debate has persisted for decades without randomized data. The SNAP platform trial just ended it.
1,341 adults with MSSA bacteremia across more than 150 hospitals in 8 countries were randomized to cefazolin or antistaphylococcal penicillin (flucloxacillin or cloxacillin). 90-day all-cause mortality: 15% (97/654) with cefazolin versus 17% (109/642) with antistaphylococcal penicillin — adjusted OR 0.81 (95% CI 0.59–1.12), with 99.2% posterior probability of non-inferiority and 89.8% probability of superiority. Acute kidney injury: 13.9% versus 19.6% (adjusted OR 0.67; 95% CI 0.50–0.89; 99.7% posterior probability of superiority) — the antistaphylococcal-penicillin arm was discontinued early on this safety signal.
Practice implication: Cefazolin is now the evidence-based first-line backbone for MSSA bacteremia in most patients. Physicians may want to consider cefazolin preferentially unless specific contraindications apply, such as CNS involvement where inoculum-effect concerns remain relevant.
2. OCEANIC-STROKE: A Factor XIa Inhibitor Cuts Recurrent Stroke Without Increasing Bleeding
Neurology
The search for a safer anticoagulant option after noncardioembolic stroke has a promising answer — the first positive Phase 3 trial of a Factor XIa inhibitor for secondary stroke prevention.
12,327 patients were randomized within 72 hours of noncardioembolic ischemic stroke or high-risk TIA across 37 countries, on background antiplatelet therapy, to asundexian or placebo (median follow-up 567 days). Ischemic stroke: 6.2% asundexian versus 8.4% placebo — cause-specific HR 0.74 (95% CI 0.65–0.84; P<0.001). Major bleeding: 1.9% versus 1.7% — HR 1.10 (95% CI 0.85–1.44), no significant increase.
Practice implication: Asundexian is not yet approved, but this trial signals a near-future add-on to antiplatelet therapy that meaningfully lowers recurrent ischemic stroke without a bleeding penalty — a paradigm-level shift for secondary stroke prevention. Physicians managing post-stroke and TIA patients may want to follow regulatory developments closely.
3. TRANSCEND-T2D-1: A Triple Hormone Receptor Agonist Delivers Large Glycemic and Weight Benefits as First-Line Monotherapy
Endocrinology
Retatrutide — a GIP, GLP-1, and glucagon receptor triple agonist — just demonstrated striking simultaneous glycemic and weight effects as stand-alone first-line therapy for type 2 diabetes.
537 adults with early type 2 diabetes inadequately controlled on diet and exercise alone (A1c 7.0–9.5%; ~85% treatment-naïve) were randomized to retatrutide 4 mg, 9 mg, or 12 mg versus placebo for 40 weeks. Mean A1c reductions: −1.69%, −1.86%, and −1.94% versus −0.81% with placebo. Mean weight loss up to 15.3% at the highest dose (12 mg), representing approximately 36 lbs on average. Distinct from the previously covered orforglipron (ACHIEVE-3, April 2026) — retatrutide is a triple agonist where orforglipron is a pure GLP-1 receptor agonist.
Practice implication: The triple agonist approach compounds glycemic and weight benefits beyond what single-receptor agents achieve. Physicians may want to monitor the regulatory pathway for retatrutide, particularly for earlier-line use in patients where both glycemic control and significant weight reduction are treatment goals.
4. NordICC 13-Year: Colonoscopy Prevents Cancer but the Mortality Signal Remains Elusive
Preventive Medicine / Gastroenterology
The only large randomized trial of screening colonoscopy now has 13 years of follow-up — and the results should change how internists counsel patients about what colonoscopy can and cannot promise.
84,583 adults aged 55–64 in Norway, Poland, and Sweden were randomized 1:2 to a single colonoscopy invitation versus no screening. At 13 years, CRC incidence: 1.46% versus 1.80% — intention-to-screen RR 0.81 (95% CI 0.71–0.90); per-protocol RR 0.55 (95% CI 0.33–0.81). CRC mortality: 0.41% versus 0.47% — RR 0.88 (95% CI 0.68–1.08), not statistically significant. Only 42% of those invited actually underwent colonoscopy, diluting the intention-to-screen estimate, and the trial was underpowered for mortality because baseline CRC mortality came in far below design assumptions.
Practice implication: Colonoscopy demonstrably reduces colorectal cancer incidence, but the RCT evidence for a mortality benefit remains unproven at 13 years. Physicians may want to calibrate shared-decision conversations accordingly — colonoscopy prevents cancer but the survival benefit assumed from decades of observational data has yet to be confirmed in a randomized trial.
5. SYNCHRONIZE-MASLD: Survodutide Delivers Large Liver-Fat and Weight Reductions in MASLD
Hepatology
MASLD is increasingly prevalent in general medicine clinics and has historically had limited pharmacologic options. Survodutide — a glucagon/GLP-1 dual agonist — just produced some of the largest liver-fat reductions seen in a Phase 3 MASLD trial.
216 adults with obesity and at-risk MASLD were randomized 2:1 to once-weekly subcutaneous survodutide 6.0 mg or placebo for 48 weeks. ≥30% reduction in MRI-PDFF liver fat: 84.2% versus 24.3% (P<0.0001). Mean body-weight change: −12.2% versus −1.0% (P<0.0001). Adverse events were predominantly mild-to-moderate GI effects during dose escalation.
Practice implication: The liver-fat reduction signal is striking, though histologic and hard outcome data are still needed and the trial enrolled only 216 patients. Physicians may want to consider this an important signal while awaiting confirmatory data — survodutide joins a growing field of metabolic agents being evaluated for MASLD with cardiovascular and hepatic outcomes as the ultimate benchmark.
CLINICAL PEARLS THAT MATTER
Finerenone's Heart Failure Benefit Holds Across the Blood Pressure Spectrum (Cardiology) — Prespecified analysis of FINEARTS-HF (JAMA Cardiology, July 8, 2026) found finerenone's benefit in HFmrEF/HFpEF was consistent and largely independent of baseline blood pressure, with the cardiovascular composite benefit maintained across BP categories from <120 to ≥140 mmHg. Physicians may want to consider that blood pressure alone should not be a barrier to deploying finerenone in otherwise eligible heart failure patients. FINEARTS-HF Analysis - JAMA Cardiology
Medical Cannabis Shows No Benefit for Anxiety, Depression, or PTSD (Psychiatry / General IM) — Systematic review and meta-analysis of 54 RCTs (2,477 participants, Lancet Psychiatry) found no evidence of efficacy for cannabinoids across anxiety, depression, or PTSD. A low-certainty positive signal was noted for cannabis use disorder specifically. All-cause adverse events were more common with cannabinoids (OR 1.75; 95% CI 1.25–2.46), though serious adverse events and study withdrawals did not differ significantly from controls. Overall conclusion: routine use of cannabinoids for mental disorders is rarely justified. Cannabinoids Meta-Analysis - The Lancet Psychiatry
Dapirolizumab Pegol Meets Primary Endpoint in Active SLE (Rheumatology) — PHOENYCS GO (321 adults with moderate-to-severe active SLE despite standard of care, randomized 2:1 to IV dapirolizumab pegol vs placebo) showed BICLA response at week 48 in 50% versus 35% — treatment difference 14.6 (95% CI 3.3–25.8; P=0.011). A first-in-class CD40 ligand inhibitor adds to the growing lupus treatment toolkit; internists co-managing lupus patients may want to track its regulatory pathway. PHOENYCS GO - The Lancet
MONDAY MORNING ROUNDS: 5 KEY DISCUSSION POINTS
Cefazolin matched antistaphylococcal penicillin for 90-day mortality in MSSA bacteremia (OR 0.81; 89.8% probability of superiority) while causing significantly less AKI (13.9% vs 19.6%; OR 0.67) — the antistaphylococcal-penicillin arm was stopped early for safety.
Asundexian reduced recurrent ischemic stroke by 26% (6.2% vs 8.4%; HR 0.74; P<0.001) on top of antiplatelet therapy in 12,327 post-stroke/TIA patients without increasing major bleeding — the first positive Phase 3 FXIa inhibitor trial for stroke prevention.
Retatrutide as first-line monotherapy reduced A1c by up to 1.94% and body weight by up to 15.3%(approximately 36 lbs) in treatment-naïve type 2 diabetes — the triple GIP/GLP-1/glucagon agonist approach delivers substantially larger combined metabolic effects than single-receptor agents.
Colonoscopy reduced CRC incidence by 19% at 13 years (RR 0.81; 95% CI 0.71–0.90) but did not significantly reduce CRC mortality (RR 0.88; 95% CI 0.68–1.08) — the largest and longest RCT of screening colonoscopy to date.
Survodutide achieved ≥30% liver-fat reduction in 84.2% of MASLD patients versus 24.3% with placebo, with 12.2% body-weight loss — the strongest liver-fat signal yet in a Phase 3 MASLD trial.
The content provided in The Rounds Report is for educational and informational purposes only and does not constitute medical advice, diagnosis, treatment recommendations, or professional medical guidance. This newsletter presents summaries and analysis of published medical research and should not be used as a substitute for professional medical judgment, clinical decision-making, or consultation with qualified healthcare providers. Always consult with appropriate medical professionals and refer to original research sources before making any clinical decisions. The Rounds Report does not establish a doctor-patient relationship and readers should not rely on this content for patient care decisions.
© 2026 The Rounds Report. All rights reserved.